Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 3/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447120 | 0.83 | NPC1 (0.41) | CSF1RNPC1RAB9APDE2AMAOB | |
| SCHEMBL23949942 | 0.80 | MAOB (0.46) | NPC1RAB9AMAOBMAOAAPP | |
| SCHEMBL1672592 | 0.79 | PDE10A (0.43) | — | |
| SCHEMBL29447095 | 0.78 | MAOB (0.50) | CSF1RNPC1RAB9AMAOBAPP | |
| SCHEMBL29620984 | 0.77 | MAOB (0.50) | CSF1RNPC1RAB9AMAOBMAOA | |
| SCHEMBL22925872 | 0.77 | MAOB (0.50) | CSF1RNPC1RAB9AMAOBMAOA | |
| SCHEMBL29620899 | 0.77 | MAOB (0.44) | CSF1RNPC1RAB9APDE2AMAOB | |
| SCHEMBL22925751 | 0.77 | MAOB (0.44) | CSF1RNPC1RAB9APDE2AMAOB | |
| SCHEMBL1566809 | 0.77 | APP (0.51) | NPC1RAB9APDE2AMAOBAPP | |
| SCHEMBL28694513 | 0.77 | LRRK2 (0.40) | CSF1RNPC1RAB9APDE2ANTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509460-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-3920926-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163541-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | CSF1R 3897/4885NPC1 2258/4885RAB9A 3071/4885 |
| US-12509460-B2 | Methods and compositions for modulating splicing | SF3B1, RTCB, RBM17 | CSF1R 3699/4885NPC1 1286/4885RAB9A 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.